Fourney R, Palmer M, Ng A, Dietrich K, Belch A, Paterson M, Brox L
Department of Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada.
Dis Markers. 1990 May-Jun;8(3):117-24.
Oncogene analyses of four human myeloma cell lines provided no indication of gene amplification or rearrangement using DNA probes for the met, raf, abl, mos, erb B, Her-2-neu, fos, myb-7, fms, L-myc, sis, and myb-1 genes. However, a consistent elevation of up to 23-fold in the level of c-myc mRNA was observed in all of the cell lines studied. No restriction fragment length polymorphism (in exons one, two, or three) or c-myc gene amplification has as yet been demonstrated to account for the c-myc mRNA elevation. The c-myc mRNA has a half-life of 25 min which is comparable to that observed in other systems. The elevation in c-myc mRNA is further evidence for the role of the c-myc proto-oncogene in the pathogenesis of myeloma.
对四个人类骨髓瘤细胞系进行的癌基因分析显示,使用针对met、raf、abl、mos、erb B、Her-2-neu、fos、myb-7、fms、L-myc、sis和myb-1基因的DNA探针,未发现基因扩增或重排迹象。然而,在所研究的所有细胞系中均观察到c-myc mRNA水平一致升高,最高可达23倍。目前尚未证实外显子1、2或3中的限制性片段长度多态性或c-myc基因扩增可解释c-myc mRNA的升高。c-myc mRNA的半衰期为25分钟,与其他系统中观察到的半衰期相当。c-myc mRNA的升高进一步证明了c-myc原癌基因在骨髓瘤发病机制中的作用。